Search

Search

Popular peptides
↑ ↓ to move ↵ to openBrowse all peptides

Why most peptides aren’t FDA approved

“Not FDA approved” sounds like a warning. For most peptides it means something simpler: no company has paid for the trials the FDA requires, and the rules give them little reason to.

Updated · 72 sources

The short version

  1. Approval is a yes to one product, for one disease. The company has to prove it in trials with up to thousands of people. Counting the drugs that fail along the way, that comes to about a billion dollars per approved drug.1 Why it costs so much
  2. Most of these peptides can’t be patented. They’re natural molecules or pieces of them, and since a 2013 Supreme Court ruling, finding something in nature isn’t enough to patent it.2 Without a patent, a company has little hope of earning back what the trials cost. More on patents
  3. Many are used for things the FDA doesn’t treat as diseases, like recovery, aging or focus. An approved label has to name a recognized disease or condition.3 More on the disease rule
  4. So for most of them, the FDA hasn’t said no to approval. Nobody has asked. That doesn’t prove they’re safe or that they work, which is why the evidence on each profile, and your doctor, matter. What the research shows

What “FDA approved” actually means

It’s the FDA saying yes to one company’s product, for one specific use, after the company proves it with its own trials.

  • The company does the testing. The FDA sets the rules and reviews the evidence, but it doesn’t test drugs itself. The company runs the trials and pays for them.4
  • It covers one use. By law, the trials have to show the drug works under the conditions on its label: a named condition, in named patients, at a named dose.5 Semaglutide was approved as Ozempic for type 2 diabetes in 2017. Using it for weight loss took a separate approval, Wegovy, in 2021.67
  • It covers one product. The approval belongs to a specific maker’s product, made a specific way. It doesn’t cover a compounded version, mixed by a pharmacy for individual patients: in the FDA’s words, “Compounded drugs are not FDA-approved.” Nor does it cover a vial of the same molecule sold online “for research use only.”89
  • Doctors can still prescribe other uses. Once a drug is approved, doctors may prescribe it “off label” for other uses when they judge it’s right for the patient. Those uses haven’t been through the FDA’s review.10
  • “Not approved” isn’t “rejected.” For most peptides on PepSavvy, no company has run the large trials an application needs, so the FDA has never ruled on whether they work.

“Drug companies seeking to sell a drug in the United States must first test it. The company then sends CDER the evidence from these tests to prove the drug is safe and effective for its intended use.”

U.S. Food and Drug AdministrationHow drug approval works. CDER is the FDA’s center that reviews new drugs.4
What it takes to get a drug approved

  1. Lab and animal studies

    Before anyone takes a dose

    Is it worth testing in people?

  2. Phase 1

    20 to 100 people · Several months

    Safety and dose

    About 70% move on

  3. Phase 2

    Up to several hundred people · Several months to 2 years

    Does it work? Side effects

    About 33% move on

  4. Phase 3

    300 to 3,000 people · 1 to 4 years

    Proof it works, rarer side effects

    25–30% move on

  5. FDA review

    A $4.6 million fee just to apply11

    Approved for that use, in that product

Percentages are the share of drugs that make it to the next phase.12

Reason 1: nature can’t be patented

Most popular peptides are natural molecules or pieces of them. Natural things can’t be patented, so a company that paid for the trials would have little way to stop others from selling the same peptide.

  • The 2013 ruling. In Association for Molecular Pathology v. Myriad Genetics, the Supreme Court ruled 9–0 that a company can’t patent a human gene just because it was the first to isolate it.2
  • The same rule covers peptides. The next year, the U.S. Patent Office applied the ruling to all natural products and listed “proteins and peptides” among them.13 Today, something taken from nature can be patented as a product only if it has “markedly different characteristics” from the natural version.14
  • The popular ones come from the body. BPC-157 is a piece of a protein found in human stomach juice. TB-500 is a fragment of thymosin beta-4, which your body makes. GHK-Cu circulates in human blood, and KPV is a three-amino-acid piece of a hormone called α-MSH.15
  • Being well studied works against a patent, too. An invention can’t be patented once it has been described in a publication or otherwise made public.16 The published research that makes these peptides interesting also makes them hard to own.
  • What can be patented doesn’t protect much. A company could patent a new use for a peptide. But generic makers can still sell the same molecule, labeled only for its unpatented uses, and doctors often treat the versions as interchangeable. A 2026 Supreme Court case, Hikma v. Amarin, shows how that plays out.17 Without a patent, approval brings just 5 years of exclusivity, the FDA’s protection from generic copies, after development that often takes a decade or more.1819
  • That’s how the GLP-1 drugs got around it. Natural GLP-1 lasts only minutes in the body.20 Semaglutide swaps two of its amino acids and adds a fatty acid, so it lasts about a week and counts as a new molecule a company can patent.152122
  • Without protection, new uses stop getting tested. Once a medicine’s patents run out, companies rarely seek approval for new uses. One study found new approved uses for existing drugs fell to near zero after generics arrived.2324

“Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention.”

Justice Clarence ThomasFor a unanimous Supreme Court, 20132

Reason 2: proving it costs a fortune

Bringing one new drug to approval costs around a billion dollars once the failures are counted, and most drugs that start human trials never make it.

Why a new drug costs about $1 billionThe final trial is only a small part. Most of the money goes to drugs that fail, and to years of waiting before any comes back.
  1. One final, large trialtypical cost$19 million
  2. Total cost of getting one drug approvedtypical for 63 drugs approved 2009–2018$985 million
  3. Total cost of getting one drug approvedaverage from a survey of 10 drug companies, in 2013 dollars$2.6 billion

Both totals include the drugs that failed along the way and the cost of having the money tied up for years. The survey’s $2.6 billion is $1.4 billion spent plus $1.2 billion for the wait.12526

Of 100 drugs that start human trials, only 8 to 12 get approved
  • Approved (8, by the industry’s count)
  • Also approved by the government’s count (4 more, so 12 in all)
  • Dropped along the way (88 to 92)

The Congressional Budget Office puts approval at about 12%. An industry analysis of 9,704 drug programs found 7.9%.1927

  • About a billion dollars per approved drug. A study of 63 drugs approved from 2009 to 2018 found a typical cost of $985 million each.1 A Tufts University survey of 10 drug companies put the average at $2.6 billion, in 2013 dollars: $1.4 billion actually spent, plus $1.2 billion for what that money could have earned while it was tied up.26 Both totals count the drugs that failed along the way. The final, large trials themselves typically cost $19 million each, a small share of the total.25
  • Most drugs fail. Only about 12% of drugs that enter human trials are approved, roughly 1 in 8.19 An industry analysis of 9,704 programs put it at 7.9%, about 1 in 13.27
  • The money goes out for years before any comes back. In the Congressional Budget Office’s words, “The development process often takes a decade or more, and during that time the company does not receive a financial return on its investment in developing that drug.”19
  • Money decides what gets tested. In the decade before the 1983 Orphan Drug Act, there were “only ten” FDA-approved treatments for rare diseases.28 Congress later found that drugmakers “could rarely make a profit from marketing drugs for such small groups of patients.”29 The law gave orphan drugs 7 years of exclusivity.18 By 2017, more than 600 rare-disease uses had been approved, and from 2018 to 2023, 186 of the 356 new drugs the FDA approved (52%) were orphan drugs.2830
  • Even a cheap, common drug can’t get funded. Researchers want to test whether metformin, a generic diabetes pill, slows aging. The trial, called TAME, needs $45–70 million. No company can profit from generic metformin, and as of 2024 the trial still hadn’t started.3132

“Nobody’s going to fund a $2 billion trial for a compound they can’t protect.”

Dr. Alex Tatem, MDUrologist, on the cost of all three phases of trials, in the video at the end of this page15

Reason 3: the FDA approves treatments for diseases

Every approved drug has to name the recognized disease or condition it’s for. Faster recovery, slower aging and sharper focus aren’t diseases, so a company would first have to pick a specific condition and prove the peptide works for that.

“…the drug is indicated for the treatment, prevention, mitigation, cure, or diagnosis of a recognized disease or condition…”

FDA labeling rule, 21 CFR 201.57What every approved label must say3
  • A trial needs a named condition to beat. The final phase enrolls 300 to 3,000 people who have the condition, to show the drug treats it better than a placebo (a dummy treatment) or the usual treatment.1215
  • Aging isn’t on the list. The FDA doesn’t class aging as a disease, so the metformin trial above has to measure whether metformin delays age-related diseases, such as heart disease, cancer and cognitive decline, instead.31
  • That’s why approved peptides look so narrow. Melanotan I is approved, but as an implant for a rare disease that makes sunlight painful, not for tanning.33 Tesamorelin is approved for belly fat in people with HIV, not for fat loss in general.34 More examples
  • Each use needs its own trial, and trials can miss. In a trial after bowel surgery, people given ipamorelin typically managed their first meal after 25.3 hours, versus 32.6 hours for those given a placebo. The difference was too small to rule out chance, so the trial couldn’t show it works for that use.35
  • Fixing the patent problem wouldn’t be enough. As Dr. Tatem points out, even a patentable peptide would still need a recognized disease to be approved for.15

When peptides do get approved

Peptides aren’t fringe medicine: more than 80 peptide drugs have reached the market worldwide, from insulin to the GLP-1 drugs.36 They get approved like any other drug when a company can own the molecule and aim it at a disease.

  • Semaglutide
    • Ozempic, 2017: Type 2 diabetes (blood sugar control)6
    • Wegovy, 2021: Chronic weight management7
  • Tirzepatide
    • Mounjaro, 2022: Type 2 diabetes (blood sugar control)37
    • Zepbound, 2023: Chronic weight management38
  • Tesamorelin
    • Egrifta, 2010: Extra belly fat in people with HIV-related lipodystrophy34
  • SS-31
    • Forzinity (elamipretide), 2025: Muscle strength in Barth syndrome, a rare genetic disease39
  • Melanotan I
    • Scenesse (afamelanotide), 2019: Painful reactions to light in a rare disease called EPP33

    Approved as an implant, not as research vials for tanning.

  • PT-141
    • Vyleesi (bremelanotide), 2019: Distressing low sexual desire in premenopausal women40
  • Oxytocin
    • Pitocin, 1980: Starting or strengthening labor for medical reasons, and controlling bleeding after birth41

    The 1980 approval was for a new version of an already-approved drug.

  • Sermorelin
    • Geref, 1997: Growth hormone deficiency in children42

    Discontinued in 2008. The FDA later found it wasn’t withdrawn for safety or effectiveness reasons.

Each approval covers that product, for that condition. It doesn’t cover a research vial of the same peptide.

Does “not approved” mean unsafe?

No. It means unproven. Most of these peptides have been studied in animals, cells or small groups of people, and that research is encouraging for some. It just isn’t proof.

37 of 42

peptides on PepSavvy with no FDA-approved product have published research in animals or people. 25 have at least small human studies. The other 5 are variants that haven’t been studied in their exact form.

  • Solid human studies4
  • Few human studies21
  • Mostly animal studies12
  • Untested in people5

From each profile’s research level. How we rate

  • Some are medicines in other countries. Thymosin alpha-1 has been approved in more than 30 countries, mainly for hepatitis B, but isn’t part of any FDA-approved drug.4344 Semax is on Russia’s list of essential medicines, and Selank is sold there for anxiety.4546
  • Some are already in everyday products. GHK-Cu is widely used in anti-wrinkle skin care.47 Cosmetics don’t need FDA approval, so it’s on store shelves without ever being an approved drug.48
  • Animal safety studies are encouraging. In mice, rats, rabbits and dogs, BPC-157 caused no serious toxicity, even after 28 days of injections, and tests for gene damage were negative.49 FDA reviewers still called the animal studies “too limited in scope and duration to inform safety considerations” for people.50

“No serious adverse events appear to have been reported with these studies. However, these studies were of short duration, had small sample sizes, evaluated doses that were likely exploratory in nature, and the authors provided limited information on safety data.”

FDA reviewersOn the human studies of BPC-157, July 202650
  • Better trials are starting. A placebo-controlled trial of BPC-157 for hamstring strains began recruiting about 120 people in February 2026.51
  • What the FDA actually said. When the FDA listed BPC-157 as a substance that may be risky to compound, it didn’t say the peptide was proven harmful. It said “the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.”52 Its reviewers did raise real concerns: possible immune reactions, impurities from manufacturing, and side effects reported to the FDA, though they said it’s unclear whether BPC-157 caused them.50

What we still don’t know

Without large human trials, nobody can say for sure how well these peptides work, which doses are right, or what happens after years of use.

“Because these studies are larger and longer in duration, the results are more likely to show long-term or rare side effects.”

U.S. Food and Drug AdministrationOn phase 3 trials12
  • Small studies miss rare problems. To be 95% sure a side effect affects no more than 1 in 1,000 people, you need about 3,000 people without a single case.55 The three published human studies of BPC-157 had 30 people between them.56
  • Animal results often don’t carry over to people. Of 367 treatments tested in animals, about half were ever tried in people, and 5% were approved.57
  • Interactions are mostly untested, both with medicines and with other peptides.
Ruling out a 1-in-1,000 side effect takes about 3,000 people
  • All three published human studies of BPC-157: 30 people in total
  • The whole grid, about 3,000 people: enough to be 95% sure a side effect affects no more than 1 in 1,000

Each square is 30 people.5556

Only 5% of treatments tested in animals become approved
  1. Tested in animals100%
  2. Tried in any human studytypically 5 years later50%
  3. Tested in a randomized trial, the strongest kind7 years later40%
  4. Approved10 years later5%

From 367 treatments for 54 diseases, followed through 122 reviews of the research.57

Talk to a doctor before you start anything, especially if you take other medicines, are pregnant or trying to be, or have a health condition. PepSavvy is an educational reference, not medical advice.

What the community adds

A large and growing community has used these peptides on themselves for years and compared notes. That experience is worth something. It just isn’t the same as a trial.

  • It’s growing fast. In doctors’ notes, new BPC-157 users rose about 33 times over from 2020 to 2026, and about a third of those whose source was recorded got it from gray-market sellers. That study isn’t peer reviewed yet.58
  • What it’s good for. Shared experience shows what people commonly notice, which side effects keep coming up, and which questions deserve a proper trial. PepSavvy uses community reports that way, and labels them. How we use them
  • What it can’t show. Reports come from people who chose to share them. Doses, product quality and other medicines usually go unrecorded, and without a placebo group it’s hard to tell a peptide’s effect from time, expectation or chance.
  • Silence isn’t proof of safety. Even for approved drugs, a review of 37 studies found that typically 94% of side effects never get reported.59 A quiet community record doesn’t mean nothing went wrong.

Where things stand in 2026

Pharmacies may soon be allowed to make some popular peptides again. Dr. Tatem calls that a meaningful step toward safety over the gray market, but it still wouldn’t make them FDA approved.815

Right now · October 16, 2026

Pharmacies still can’t make BPC-157, TB-500 or the other peptides the FDA restricted in 2023.52 A draft policy that would let them make some for now, reportedly including BPC-157, is under review at the White House.60

  1. 2012

    Contaminated steroid shots from a Massachusetts compounding pharmacy cause a fungal meningitis outbreak: 753 cases and 64 deaths in 20 states.61

  2. Nov 2013

    Congress responds with the Drug Quality and Security Act, which sets up today’s two tiers of compounding pharmacies.62

  3. 2014–2023

    While the FDA reviews which substances pharmacies may use, doctors can prescribe many popular peptides from compounding pharmacies.15

  4. Sep 2023

    The FDA moves 19 substances, mostly popular peptides such as BPC-157 and TB-500, into a category of substances that may present significant safety risks. Pharmacies have to stop making them.1552

  5. 2024

    Five, including CJC-1295 and ipamorelin, are withdrawn by the groups that nominated them, and the FDA’s advisers vote against adding several of them to the list pharmacies may use.526364

  6. Feb 2026

    Health Secretary Robert F. Kennedy Jr. says on The Joe Rogan Experience that about 14 peptides will become easier to get.15

  7. Apr 2026

    Twelve more, including BPC-157 and TB-500, are withdrawn and leave the risk list. That leaves them in limbo, not approved for compounding. The FDA sends seven to its advisory committee.5265

  8. Jul 2026

    The committee narrowly votes to let pharmacies use six of the seven, including BPC-157, TB-500 and Semax, against the advice of FDA staff. The vote is advice, not a decision.5066

  9. Oct 2026

    HHS and the FDA send the White House a draft interim policy that would reportedly let pharmacies make some popular peptides, including BPC-157, for now. Its details aren’t public yet.60

  10. Next

    Making it permanent takes formal rulemaking. And even then, a compounded peptide isn’t FDA approved.860

A lawsuit that could keep GLP-1 prices high

Eli Lilly is in court trying to get its next obesity drug, retatrutide, regulated as a biologic, the category for proteins longer than 40 amino acids, instead of as a drug.6768 If Lilly wins, it would get 12 years of protection from cheaper copies instead of 5, and pharmacies could never compound it.8186970 Dr. Tatem argues that would keep GLP-1 prices high for years, as the same switch did for hCG in 2020.1571

Read the full storyWhy Eli Lilly is suing the FDA over retatrutideWhat the case is about, where it stands, and how to tell your senators what you think

What this means for you

Read “not FDA approved” as “not proven by large trials”, not as “dangerous” and not as “useless”.

  • Check the evidence for the peptide you’re considering. Each profile shows what was studied, in whom, and what’s still unknown.
  • Be wary of “research use only” vials. They’re sold outside the rules for drugs, with no regulator checking what’s in them, and lab tests find many fail basic quality checks.53 What each kind of vial guarantees
  • Talk to a doctor, and bring the profile. Be open about what you take, including anything bought online.
  • Competing in a tested sport? The World Anti-Doping Agency bans substances with no government approval for human use at all times, and names BPC-157 as an example.72 Which peptides are banned
WatchIt’s Official: 7 Life-Changing Peptides are BACK.Dr. Alex Tatem · MD · Urologist · Apr 2026 · opens at 22:51, the part on why drug companies won’t fund peptide trials(on YouTube, opens in a new tab)

Sources

Quotes are word for word. Tap a number anywhere on this page to see its source.

All sources72
  1. Estimated research and development investment needed to bring a new medicine to market, 2009–2018Paper · 2020(opens in a new tab)
  2. Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 576 (2013)Court ruling · 2013(opens in a new tab)
  3. 21 CFR 201.57: Indications and usage on drug labelsRegulation · 2006(opens in a new tab)
  4. FDA: Development & Approval Process (Drugs)Regulator · 2022(opens in a new tab)
  5. 21 U.S.C. § 355: New drugs ("substantial evidence")Law · 1962(opens in a new tab)
  6. FDA approval letter: Ozempic (semaglutide), NDA 209637Regulator · 2017(opens in a new tab)
  7. FDA approval letter: Wegovy (semaglutide), NDA 215256Regulator · 2021(opens in a new tab)
  8. FDA: Compounding and the FDA, questions and answersRegulator · 2025(opens in a new tab)
  9. FDA: Is it really “FDA approved”?Regulator · 2026(opens in a new tab)
  10. FDA: Understanding unapproved use of approved drugs (“off label”)Regulator · 2018(opens in a new tab)
  11. Prescription drug user fee rates for fiscal year 2027 (Federal Register)Regulator · 2026(opens in a new tab)
  12. FDA: Step 3, Clinical ResearchRegulator · 2018(opens in a new tab)
  13. USPTO: Guidance for determining subject matter eligibility of claims involving natural products (March 2014)Government guidance · 2014(opens in a new tab)
  14. USPTO: Manual of Patent Examining Procedure § 2106.04, products of natureGovernment guidance · 2024(opens in a new tab)
  15. It’s Official: 7 Life-Changing Peptides are BACK. (Dr. Alex Tatem, MD)Video · 2026(opens in a new tab)
  16. 35 U.S.C. § 102: Conditions for patentability; noveltyLaw · 2011(opens in a new tab)
  17. Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)Court ruling · 2026(opens in a new tab)
  18. FDA: Frequently asked questions on patents and exclusivityRegulator · 2026(opens in a new tab)
  19. CBO: Research and development in the pharmaceutical industryGovernment report · 2021(opens in a new tab)
  20. Engineering and characterization of the long-acting GLP-1 analogue LY2189265, an Fc fusion proteinPaper · 2010(opens in a new tab)
  21. Discovery of the once-weekly GLP-1 analogue semaglutidePaper · 2015(opens in a new tab)
  22. Wegovy FDA prescribing information, 2026Regulator · 2026(opens in a new tab)
  23. On-label or off-label? Overcoming regulatory and financial barriers to bring repurposed medicines to cancer patientsReview · 2020(opens in a new tab)
  24. Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997Paper · 2021(opens in a new tab)
  25. Estimated costs of pivotal trials for novel therapeutic agents approved by the FDA, 2015–2016Paper · 2018(opens in a new tab)
  26. Innovation in the pharmaceutical industry: new estimates of R&D costsPaper · 2016(opens in a new tab)
  27. Clinical development success rates and contributing factors 2011–2020Industry report · 2021(opens in a new tab)
  28. FDA: Orphan Drug Modernization PlanRegulator · 2017(opens in a new tab)
  29. Rare Diseases Orphan Product Development Act of 2002, congressional findings (note to 21 U.S.C. § 360ee)Law · 2002(opens in a new tab)
  30. GAO: Rare disease drugs, FDA has steps underway to strengthen coordination of activities supporting drug developmentGovernment report · 2024(opens in a new tab)
  31. STAT: Anti-aging projects draw funding, but a much-discussed trial is overlookedNews · 2022(opens in a new tab)
  32. NPR: A cheap drug may slow down aging. A study will determine if it worksNews · 2024(opens in a new tab)
  33. FDA approval letter: Scenesse (afamelanotide) implant, NDA 210797Regulator · 2019(opens in a new tab)
  34. FDA approval letter: Egrifta (tesamorelin), NDA 022505Regulator · 2010(opens in a new tab)
  35. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientsTrial · 2014(opens in a new tab)
  36. Trends in peptide drug discoveryReview · 2021(opens in a new tab)
  37. FDA approval letter: Mounjaro (tirzepatide), NDA 215866Regulator · 2022(opens in a new tab)
  38. FDA approves new medication for chronic weight management (Zepbound)Regulator · 2023(opens in a new tab)
  39. FDA grants accelerated approval to first treatment for Barth syndrome (Forzinity)Regulator · 2025(opens in a new tab)
  40. FDA approval letter: Vyleesi (bremelanotide), NDA 210557Regulator · 2019(opens in a new tab)
  41. Drugs@FDA: Pitocin (oxytocin injection), NDA 018261Regulator · 1980(opens in a new tab)
  42. FDA determination that Geref (sermorelin acetate) was not withdrawn for reasons of safety or effectivenessRegulator · 2013(opens in a new tab)
  43. SciClone Pharmaceuticals annual report (Form 10-K), 2016Company report · 2017(opens in a new tab)
  44. FDA briefing document on thymosin alpha-1, Pharmacy Compounding Advisory Committee, December 2024Regulator · 2024(opens in a new tab)
  45. The potential of the peptide drug Semax and its derivative for correcting pathological impairments in the animal model of Alzheimer’s diseaseAnimal or lab study · 2025(opens in a new tab)
  46. Selank (Vidal drug reference, Russia)Drug reference · 2026(opens in a new tab)
  47. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospectiveReview · 2025(opens in a new tab)
  48. FDA: Is it a cosmetic, a drug, or both? (Or is it soap?)Regulator · 2024(opens in a new tab)
  49. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various woundsAnimal or lab study · 2020(opens in a new tab)
  50. FDA briefing document on BPC-157, Pharmacy Compounding Advisory Committee, July 2026Regulator · 2026(opens in a new tab)
  51. BPC 157 for acute hamstring muscle strain repair (NCT07437547)Trial registry · 2026(opens in a new tab)
  52. FDA: Certain bulk drug substances for use in compounding that may present significant safety risksRegulator · 2026(opens in a new tab)
  53. Evaluation of research grade peptides marketed directly to consumers reveals extensive variability in purity and measured abundance (preprint)Preprint · 2026(opens in a new tab)
  54. Safety and risk assessment of no-prescription online semaglutide purchasesLab analysis · 2024(opens in a new tab)
  55. FDA/CBER: Required postmarketing studies (application of pharmacovigilance to FDA regulatory decisions for vaccines)Regulator · 2012(opens in a new tab)
  56. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safetyReview · 2026(opens in a new tab)
  57. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applicationsReview · 2024(opens in a new tab)
  58. Rising use of unapproved BPC-157 (“Wolverine peptide”) and associated patient-reported outcomes curated from clinical notes (preprint)Preprint · 2026(opens in a new tab)
  59. Under-reporting of adverse drug reactionsReview · 2006(opens in a new tab)
  60. STAT: Trump administration advances plan for peptide drugs favored by RFK Jr.News · 2026(opens in a new tab)
  61. CDC: Multistate outbreak of fungal meningitis and other infections, case countGovernment report · 2015(opens in a new tab)
  62. FDA: Human drug compounding lawsRegulator · 2024(opens in a new tab)
  63. FDA: Pharmacy Compounding Advisory Committee final summary minutes, October 29, 2024Regulator · 2024(opens in a new tab)
  64. FDA: Pharmacy Compounding Advisory Committee final summary minutes, December 4, 2024Regulator · 2024(opens in a new tab)
  65. Pharmacy Compounding Advisory Committee: notice of meeting (Federal Register, April 16, 2026)Regulator · 2026(opens in a new tab)
  66. AJMC: FDA panel backs 6 peptides for compoundingNews · 2026(opens in a new tab)
  67. 21 CFR 600.3(h)(6): Definition of a proteinRegulation · 2020(opens in a new tab)
  68. Reason: Can a new weight loss treatment escape the legal and regulatory thicket?News · 2026(opens in a new tab)
  69. FDA: Background information on licensed biological products with reference product exclusivity (Purple Book)Regulator · 2020(opens in a new tab)
  70. Medical Daily: An amino acid dispute between Eli Lilly and the FDA could delay cheaper retatrutide by yearsNews · 2026(opens in a new tab)
  71. FDA: Notice to compounders, changes that affect compounding as of March 23, 2020Regulator · 2020(opens in a new tab)
  72. World Anti-Doping Agency: Prohibited ListSports regulator · 2026(opens in a new tab)
Source

Source

Open source (opens in a new tab)
Explore peptides How we source

Keep reading

Staying safeResearch peptides vs compounded vs brand-nameWhat’s actually checked in each kind of vial, what lab tests of online peptides found, and what a certificate of analysis can prove.Rules and the lawWhy Eli Lilly is suing the FDA over retatrutideThe 40-amino-acid fight that could delay cheaper versions, where the case stands, and how to tell your senators what you think.Rules and the lawWhich peptides are banned in sport?What WADA bans by name, why almost every unapproved peptide is banned too, and the status of each peptide on this site.